The world of probiotics has taken an intriguing turn with a recent study published in Nature's Communications Biology. The focus? A modified probiotic yeast, Saccharomyces boulardii, designed to be safer for immunocompromised individuals, older adults, and infants. This is a significant development, considering the potential risks associated with probiotic usage in these vulnerable populations.
Unraveling the Risks
The research team, led by Alexandra Imre, a postdoctoral researcher at North Carolina State University, delved into the cases where immunocompromised patients, infants, and the elderly experienced bloodstream infections due to probiotic use. These incidents, though rare, can have devastating consequences, even leading to fatalities. The question that prompted their investigation was clear: what makes these infections occur, and can we modify the yeast to reduce its virulence?
Genetic Modifications and Virulence Testing
The researchers examined various S. boulardii yeast cell lines, including those from commercial probiotics and clinical samples from infected patients. By infecting immunosuppressed mice with these cell lines and isolating sublineages, they identified adaptations associated with increased virulence. Interestingly, the most virulent yeast isolates were also the most tolerant to osmotic stress, specifically high salt concentrations.
The team then genetically edited the yeast, targeting two genes, ENA1 and NHA1, which play a role in osmotic stress tolerance. Deleting NHA1 had minimal impact, but deleting ENA1 significantly reduced virulence. In fact, the survival rate of mice infected with the most virulent yeast isolate increased from 30-40% to 100% after ENA1 deletion. This modification also impaired the yeast's growth under osmotic stress conditions.
Preserving Probiotic Efficacy
But what about the probiotic qualities of S. boulardii? Would these genetic modifications affect its ability to promote gut health? The researchers conducted tests using a mouse model and in vitro assays to assess the modified yeast's probiotic efficacy. They found that the genetically modified S. boulardii was just as effective as commercial probiotic strains in inhibiting the growth of bacterial pathogens commonly found in immunosuppressed patients. Additionally, the modified strain demonstrated its potential as a probiotic supplement by surviving in the gut.
A Step Towards Safer Probiotics
Nathan Crook, an associate professor at NC State and co-author of the study, emphasized the significance of these findings. Many individuals with gut diseases also have compromised immune systems, making probiotic treatment off-limits. However, this study opens up new possibilities for engineered probiotic therapies tailored for immunocompromised patients. While further research is needed to fully understand the metabolic mechanisms behind osmotic stress tolerance and virulence, this development is a promising step towards safer probiotic options for vulnerable populations.
The University of Debrecen and North Carolina State University have recognized the commercial potential of this research, submitting an international PCT patent application. With ongoing research and development, we may soon see a new generation of probiotics that offer both efficacy and safety for those who need them most.
